Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.74 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | FABP2 | P12104 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.74 |
| ▸ | HTR2C | P28335 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.74 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8755011 | 1.00 | LMNA (0.74) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL13448835 | 1.00 | LMNA (0.74) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL4217335 | 1.00 | LMNA (0.74) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL8755498 | 1.00 | LMNA (0.74) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL8755392 | 1.00 | LMNA (0.74) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL1543120 | 1.00 | LMNA (0.74) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| Hydrochloric Acid SCHEMBL27850094 | 0.99 | LMNA (0.72) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL14871874 | 0.90 | AKR1C3 (0.76) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL24177869 | 0.89 | CYP2C19 (0.61) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL16008494 | 0.87 | AKR1C3 (0.72) | LMNAAKR1C3AKR1C2PTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5322791-A | Enantiospecific hydrolysis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1994-06-21 | — | — | US | claimed |
| EP-0227078-A1 | Process for preparing (S)-alpha-methylarylacetic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1987-07-01 | — | — | EP | claimed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| WO-2023072908-A1 | CO-CRYSTALS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | DOMPE' FARMACEUTICI SPA (IT) | 2023-05-04 | — | — | WO | disclosed |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2022-06-02 | — | — | US | disclosed |
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2022-01-06 | — | — | US | disclosed |
| EP-2878592-B1 | SYNTHESIS OF AMIDE DERIVATIVES OF SOME NONSTEROIDAL ANTIINFLAMMATORY DRUGS AS POTENTIAL PRO-DRUGS | KUECUEKGUEZEL ILKAY (TR) | 2019-02-20 | — | — | EP | disclosed |
| EP-2180788-B1 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | RIGAS BASIL (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2878592-A1 | Synthesis of amide derivatives of some nonsteroidal antiinflammatory drugs as potential pro-drugs | Kücükgüzel, Ilkay (TR) | 2015-06-03 | — | — | EP | disclosed |
| US-9012647-B2 | Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-04-21 | — | — | US | disclosed |
| EP-0100120-B1 | IMPROVEMENT IN THE PROCESS FOR PREPARING BIARYL COMPOUNDS VIA COUPLING OF AN ARYLAMINE WITH AN ARENE | Nobel Chemicals AB (SE) | 1988-02-03 | — | — | EP | disclosed |
| US-4710581-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0227078-A1 | Process for preparing (S)-alpha-methylarylacetic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1987-07-01 | — | — | EP | disclosed |
| US-4581463-A | Nucleophilic substitution process combined with additional reaction steps | ETHYL CORPORATION (US) | 1986-04-08 | — | — | US | disclosed |
| US-4542233-A | Process for preparing biaryl compounds via coupling of an arylamine with an arene | BIASCHIM S.P.A. (IT) | 1985-09-17 | — | — | US | disclosed |
| EP-0100120-A1 | Improvement in the process for preparing biaryl compounds via coupling of an arylamine with an arene | Nobel Chemicals AB (SE) | 1984-02-08 | — | — | EP | disclosed |
| US-4304931-A | ANTIINFLAMMATORY AGENTS | THE BOOTS COMPANY LIMITED (GB) | 1981-12-08 | — | — | US | disclosed |
| US-4188491-A | PREPARING 2-(4-BIPHENYLYL)PROPIONIC ACIDS BY REACTING BIPHENYLYLMAGNESIUM BROMIDES WITH SODIUM PYRUVATE, ACIDIFYING | THE BOOTS COMPANY LIMITED (GB) | 1980-02-12 | — | — | US | disclosed |
| US-4107439-A | Process for preparing arylalkanoic acid derivatives | THE UPJOHN COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | LMNA 1741/4885AKR1C3 598/4885AKR1C2 852/4885 |
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | LMNA 1741/4885AKR1C3 598/4885AKR1C2 852/4885 |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | PPOX, CYCS, SCO2 | LMNA 2754/4885AKR1C3 43/4885AKR1C2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.